Q&A
Exclusive interviews with industry leaders
-
iStock via Getty Images
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
Michael Gibney • Nov. 26, 2024 -
eranicle via Getty Images
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
Michael Gibney • Oct. 29, 2024 -
Permission granted by Katelyn Jetelina
‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
Alexandra Pecci • Oct. 9, 2024 -
Permission granted by Biocom
California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
Alexandra Pecci • Oct. 1, 2024 -
Permission granted by Roivant Sciences
Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
Michael Gibney • Sept. 26, 2024 -
Permission granted by CRI
Want better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
Michael Gibney • Sept. 24, 2024 -
Michael Vi / Getty Images via Getty Images
How Lilly’s sustainability goals come face to face with massive growth
Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.
Michael Gibney • Sept. 12, 2024 -
Permission granted by Takeda Pharmaceuticals
With a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
Alexandra Pecci • Aug. 27, 2024 -
Courtesy of 23andMe
23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
Michael Gibney • Aug. 20, 2024 -
Getty Images via Getty Images
A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
Michael Gibney • Aug. 13, 2024 -
Stock via Getty Images
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.
Amy Baxter • Aug. 7, 2024 -
Permission granted by Mubadala Capital
In biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
Meagan Parrish • July 25, 2024 -
Alex Wong / Staff via Getty Images
Bird flu puts BARDA back in the spotlight
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.
Alexandra Pecci • July 23, 2024 -
Permission granted by Amylyx
Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
Meagan Parrish • July 17, 2024 -
Permission granted by BeiGene
How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.
Michael Gibney • July 2, 2024 -
Jens Schluete via Getty Images
Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?
A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.
Michael Gibney • June 25, 2024 -
Christoph Burgstedt via Getty Images
After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners
With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.
Amy Baxter • June 24, 2024 -
Stock via Getty Images
In an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
Amy Baxter • June 3, 2024 -
Permission granted by Daiichi Sankyo
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
Meagan Parrish • May 10, 2024 -
Permission granted by AstraZeneca
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
Michael Gibney • May 8, 2024 -
Courtesy of Alltrna
How a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
Amy Baxter • April 29, 2024 -
Permission granted by Ovid Therapeutics
Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.
Meagan Parrish • April 26, 2024 -
Stock via Getty Images
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.
Amy Baxter • April 24, 2024 -
Permission granted by eClinical Solutions
How pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
Michael Gibney • April 11, 2024 -
Permission granted by Verastem
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
Michael Gibney • April 4, 2024
